〔Abstract〕 Alternative splicing (AS) is one of the important ways of post-transcriptional regulation , which can gen- erate multiple mRNA isoforms from a single gene . In recent years , many studies have shown that AS can occur in almost all types of tumors , and the abnormal expression of splicing factors is related to the disease progression of tumor patients , which may become a potential marker for judging tumor progression . Therefore , this review summa- rizes the role , molecular mechanism , clinical relevance and treatment response of AS in tumors . It is found that AS can participate in the progression of malignant tumors by regulating tumor invasion , metastasis , apoptosis , cell me- tabolism , and promoting tumor immune escape and treatment resistance , which provides a theoretical basis for the clinical application of AS . The precise identification of tumor-specific AS and the development of small molecule in- hibitors targeting specific AS isoforms may provide a new direction for precise and personalized cancer treatment.